首页> 外文期刊>Journal of applied clinical medical physics / >First clinical implementation of the Capri applicator
【24h】

First clinical implementation of the Capri applicator

机译:Capri涂药器的首次临床实施

获取原文
           

摘要

This study was to assess the Capri applicator for patients with endometrial cancer undergoing high-radiation dose treatments following external-beam radiation therapy. The Capri applicator is an inflatable vaginal cylinder with multiple channels. It is used to tailor the dose distribution to an asymmetric vaginal disease, and better spare organs at risk. Five patients with high-risk endometrial cancer were selected for this study. The patients were treated with a high dose of radiation using the Capri applicator: daily fraction of 7 Gy was prescribed for a total dose of 21 Gy. The treatment plans included radiobiological parameters such as equivalent uniform dose (EUD), normal tissue complication probability (NTCP), and tumor control probability (TCP). Based on the dose-volume histograms (DVH), we also calculated four quality factors: conformity index (CI), dose homogeneity index (DHI), dose nonuniformity index (DNR), and overdose index (OI). The TCP values range from 82.26% to 95.92%. Very low values of NTCP were observed for the bladder and rectum. The EUDs to organs at risk ranged from 4.65 Gy to 18.22 Gy for the bladder, and from 3.41 Gy from to 6.56 Gy for the rectum. The mean CI was 1.05 ( SD = 0.0008 ) . The mean DNR was 0.10 ( range 0.0 ? 0.295 , SD = 0.100 ) . The mean OI was 0.019 ( SD = 0.028 ) . The DHIs were in the range of 1.0 ? 0.754 ( mean 0.886 , SD = 0.116 ) . The use of a multichannel vaginal cylinder may not only help cover extensive vaginal disease, but also reduce the dose to the rectum. This dosimetric analysis shows that rectal doses could be reduced using a multichannel cylinder. However, the dose delivered to the bladder based on EUD calculation may be higher than that obtained with other methods. Each patient must be evaluated independently to determine if a multichannel treatment is appropriate. Clinical followup will show whether this rectal dose sparing translates into a real toxicity improvement.PACS number: 3.6.96.0
机译:这项研究旨在评估Capri涂药器对子宫内膜癌患者接受外照射治疗后接受高放射剂量治疗的情况。卡普里涂药器是具有多个通道的可充气阴道圆筒。它用于调整剂量分布以适应不对称的阴道疾病,并有更好的备用器官处于危险之中。本研究选择了五名高危子宫内膜癌患者。使用Capri涂药器对患者进行了高剂量的放射治疗:规定每日剂量为7 Gy,总剂量为21 Gy。治疗计划包括放射生物学参数,例如当量均匀剂量(EUD),正常组织并发症概率(NTCP)和肿瘤控制概率(TCP)。基于剂量-体积直方图(DVH),我们还计算了四个质量因子:合格指数(CI),剂量均一性指数(DHI),剂量不均匀性指数(DNR)和过量指数(OI)。 TCP值的范围从82.26%到95.92%。膀胱和直肠的NTCP值非常低。处于危险中的器官的EUD范围从膀胱的4.65 Gy到18.22 Gy,对于直肠的范围从3.41 Gy到6.56 Gy。平均CI为1.05(SD = 0.0008)。平均DNR为0.10(范围0.0〜0.295,SD = 0.100)。平均OI为0.019(SD = 0.028)。 DHI值在1.0? 0.754(平均值0.886,SD = 0.116)。多通道阴道圆筒的使用不仅可以帮助覆盖广泛的阴道疾病,还可以减少直肠的剂量。剂量学分析表明,使用多通道气瓶可以减少直肠剂量。但是,基于EUD计算得出的输送到膀胱的剂量可能高于其他方法获得的剂量。必须对每个患者进行独立评估,以确定多通道治疗是否合适。临床随访将显示这种直肠剂量的节省是否可以转化为真正的毒性改善。PACS编号:3.6.96.0

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号